Roche
Swiss healthcare company
F. Hoffmann-La Roche AG, commonly known as Roche (), is a Swiss multinational holding healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has shares listed on the SIX Swiss Exchange. The company headquarters are located in Basel.
Roche is the fifth-largest pharmaceutical company in the world by revenue and the leading provider of cancer treatments globally. In 2023, the company’s seat in Forbes Global 2000 was 76.
The company owns the American biotechnology company Genentech, which is a wholly owned independent subsidiary, and the Japanese biotechnology company Chugai Pharmaceuticals, as well as the United States–based companies Ventana and Foundation Medicine. Roche's revenues during fiscal year 2020, were 58.32 billion Swiss francs. Descendants of the founding Hoffmann and Oeri families own slightly over half of the bearer shares with voting rights (a pool of family shareholders 45%, and Maja Oeri a further 5% apart), with Swiss pharma firm Novartis owning a further third of its shares until 2021.
F. Hoffmann-La Roche is a full member of the European Federation of Pharmaceutical Industries and Associations.
History
Founded in 1896 by Fritz Hoffmann-La Roche, the company was known early on for producing various vitamin preparations and derivatives.
Begin with the source’s own compact description: “Roche” is swiss healthcare company. The dossier treats that line as a proposition to test through Roche, Swiss and healthcare, not as a finished interpretation.
Why this record matters
The phrase “swiss healthcare company” supplies a clear boundary for inquiry. It also exposes the unanswered questions: who defined that boundary, when it became stable and which sources sit outside it.
The record creator and administrative purpose are central evidence, because official documentation reflects both action and institutional priorities. The source revision retrieved here is dated Aug 30, 2026. The linked authority identifier is Q212646. VIAF identifies the subject as 158855466. The Library of Congress control number is n90689949. 3 of 4 selected statements include explicit references; 0 carry qualifiers and 0 use preferred rank. The first chronological checks are 2023, 2000, 2020 and 2021.
Later summaries often reconcile disputed chronology or motive more neatly than the contemporary record permits. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Compare institutional narratives with records created by participants and affected communities. Dates and formal titles are useful anchors, but not substitutes for context.
- Event chronology
- Institutional context
- Locating named record creators
Contemporary correspondence, government or organizational records, oral histories and cited historical scholarship.
Three-step research path
- Establish the record: confirm the title “Roche”, its source revision and the description used here.
- Expand the search: follow Roche primary sources, Roche archive and Roche research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Roche”?
- Which voices are present, absent or mediated by the institution?
- Who created the surviving record, and for what administrative purpose?
Search terms from this dossier
This entry incorporates text from “Roche” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.